Slides
Page 1
Investor Presentation December 31, 2025
Page 2
CAUTIONARY STATEMENT This document is current as of December 31, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. (“Organigram” or the “Company”) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada or the United States has reviewed this presentation. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation is not meant to provide a complete or comprehensive analysis of Organigram’s financial or business prospects. To the maximum extent permitted by law, none of Organigram nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. This presentation contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, including but not limited to the expectations regarding the integration and synergy realization of Motif Labs Ltd. ("Motif") and Collective Project Limited ("Collective Project"). Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this presentation. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (seewww.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Certain forward-looking information included herein may also constitute a "financial outlook" within the meaning of applicable securities legislation. Financial outlook involves statements about the Company's prospective financial performance and financial position that are based on and subject to the assumptions about future economic conditions and courses of action described above as well as management's expectations regarding a strong innovation pipeline, increasing international sales, high cannabis quality and higher potency, commercialization of FAST nano-emulsion technology in ingestible formats, and receipt of the EU-GMP certification. Such assumptions are based on management's assessment of the relevant information currently available and any financial outlook included herein is provided for the purpose of helping readers understand managements's current expectations and plans for the future as of the date hereof. The actual results of the Company's operations may vary from the amounts set forth in any financial outlook and such variances may be material. Readers are cautioned that reliance on any financial outlook may not be appropriate for other purposes, or in other circumstances and that the risk factors described above and other factors may cause actual results to differ materially from any financial outlook. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this presentation are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this presentation is made as of the date of this presentation and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The descriptions of the terms of the agreements referenced in this presentationare qualified by the terms of the agreements themselves, copies of which shall be filed under Organigram’s profile on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (seewww.sec.gov). The financial information in this document contains certain financial performance measures that are not defined by and do not have any standardized meaning under International Financial Reporting Standards ("IFRS") and are used by management to assess the financial and operational performance of the Company. These include adjusted EBITDA, adjusted gross margin (adjusted gross margin %) and free cash flow("Free Cash Flow"). The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company’s operating results, underlying performance and prospects in a similar manner to the Company’s management. As there are no standardized methods of calculating these non-IFRS measures, the Company’s approach may differ from those used by other issuers, and accordingly, the use of these measures may not be directly comparable. The most directly comparable measure to adjusted EBITDA calculated in accordance with IFRS is net income (loss). The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value adjustments. The most directly comparable measure to Free Cash Flow is net cash and restricted cash provided by (used in) operating activities. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. For further information regarding these non-IFRS measures, including definitions, and a quantitative reconciliation to the most directly comparable IFRS measure, see the information under the heading "Cautionary Statement Regarding Certain Non-IFRS Measures" and the reconciliation to IFRS measures under the heading "Financial Results and Review of Operations" in the Company's management discussion and analysis of financial conditions and results of operations for the three monthsended December 31, 2025 (the "Q1 Fiscal 2026 MD&A") incorporated by reference in this presentation and filed under Organigram's profile of SEDAR+(see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov).This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person as defined in Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”), or in any other jurisdiction in which such an offer would be illegal. Organigram’s shares have not been and will not be registered under the Securities Act. We seek safe harbour. This document may not be reproduced, further distributed or published in whole or in part by any other person. This document may only be disseminated or transmitted into any jurisdiction in compliance with, and subject to, applicable securities laws. Readers are required to ensure their compliance with applicable securities laws. This investor presentation contains information concerning our industry and the markets in which we operate, including our market position and market share, which is based on information from independent third-party sources. Although we believe these sources to be generally reliable, market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. We have not independently verified any third-party information contained herein. All dollar values are in Canadian dollars unless otherwise indicated. Figures in this presentation are approximate due to rounding.
Page 3
Q1 F26 Highlights $1.4 $5.3 Q1 F25 Q1 F26 $14.3 $23.9 Q1 F25 Q1 F26 $42.7 $63.5 Q1 F25 Q1 F26 +49% +67% +273% In millions unless otherwise indicated Net Revenue Adjusted Gross Profit1 Adjusted EBITDA1 1. Adjusted gross margin and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to cautionary statement at the beginning of this document and the Company's Q1 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS.
Page 4
Vision 2035
Page 5
Canadian Roots.Naturally Global. 13 YEARS OF RESPONSIBLE LEADERSHIP WORLD CLASS CAPABILITIES RAPID INTERNATIONAL EXPANSION GLOBAL STRATEGIC INVESTOR Founded in 2013, Organigram transitioned from a leading medical cannabis company to the #1 recreational LP by market share in Canada1 Organigram operates five advanced cultivation, production, manufacturing, and logistics facilities across Canada Organigram has achieved strong year-over-year growth in international shipments and is poised to continue the trend Organigram has received over $345 million from BAT to fund research & development and international M&A Organigram is a leader in creating innovative, differentiated products, and honing its production practices INNOVATION TRAILBLAZER 1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December, 2025.
Page 6
1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December, 2025. Canada’s#1 LP in market share1 RECREATIONAL MARKET MILLED FLOWER #1 CONCENTRATES #1 GUMMIES #3 FLOWER (including milled) #3 PRE-ROLLS (including IPRs) #2 VAPES #1
Page 7
Coast to Coast Leadership by market share Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December, 2025 EASTERN CANADA#1 CENTRAL CANADA#1 WESTERN CANADA#1 Winnipeg Facility London & Aylmer Facilities (formerly Motif) Lac-Supérieur Facility Moncton Facility
Page 8
International Distribution Germany United Kingdom Australia United States • $21 million strategic investment in German cannabis leader Sanity Group GmbH ("Sanity Group") • Exporting medical whole flower to multiple customers • Exporting medical whole flower to multiple customers • Exporting medical whole flower to multiple customers • Launching branded vape and gummy sales in Q2 Fiscal 2026 • Producing and distributing Fetch and Collective Project beverages, and happly gummies available in over 20 states • Strategic investments in Phylos Bioscience Inc. (Phylos Bioscinece") and Steady State LLC (d/b/a Open Book Extracts )("OBX")
Page 9
State-of-the-art Facilities Moncton, NB • Three-tiered, modular, strain-specific grow rooms provide the ability to control critical environmental requirements by strain • In-house cannabinoid testing, and remediation • Continue to await EU-GMP certification Lac-Supérieur, QC • Producing hang-dried, hand- trimmed, artisanal cannabis • Producing multiple hash products, including the patent- pending Rip-Strip Hash Winnipeg, MB • Edibles facility with automated cutting-edge equipment with monthly capacity of up to 4 million gummies • Ramping up beverage production capabilities Aylmer, ON Advanced capabilities & centralized manufacturing: • Hydrocarbon extraction • Refining, formulation, post-processing of minor cannabinoids • Infused and regular pre-rolls London, ON Centralized distribution hub to support growing demand and to optimize fulfillment Canada’s largest indoor cultivation
Page 10
FLOWER MILLED PRE-ROLLS INFUSED PRE-ROLLS VAPES EDIBLES HASH CONCENTRATES OILS VALUE BEVERAGES PREMIUM MAINSTREAM Portfolio of Beloved Brands Delivering strong coverage across all segments and categories
Page 11
• Award-winning mainstream brand with broad category coverage and the highest repurchase rate in the Canadian market2 • #1 Canadian vape brand by market share1 • Portfolio includes IPRs, and other 2.0 products • Premium innovation brand • First Organigram brand to launch proprietary FASTTM products which increase onset by 50% and peak effect by 2x • #3 flower brand in Canada1 • Focused on larger formats catering to quality-conscious value consumers 1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December, 2025. 2. Source: Hifyre IQ Loyalty Program (Spark Members) – December. 2025.
Page 12
1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of 30, 2025 2. Source: Hifyre IQ Loyalty Program (Spark Members) – 2025 • Award winning sparkling juices and lemonades • Supports the arts community • Value-priced soda brand with top selling flavours like cola, lemon-lime and cream soda • 1% of profits support local animal charities • Gummy brand offering low THC + functional ingredients like caffeine, chamomile extract and l-theanine to target specific mood states like socialize, relax and sleep US PORTFOLIO1 1. In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram’s U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.
Page 13
Cost Synergies on Track — and Exceeding Expectations • Consolidation of logistics and warehousing through the acquisition of the London facility – a central Canada hub for key markets • Shared procurement and supplier relationships • Optimization of manufacturing and distribution operations • Owning more of our supply chain by in-housing hydrocarbon extraction and becoming one of the top THCa producers in the country, a key ingredient in infused pre rolls, partially offset by higher biomass costs Key Financial Highlights • Approximately $15 million expected in run-rate cost synergies • Adds $87 million in sales based on trailing 12-month revenue as of acquisition date • Highly complementary innovation pipelines Fiscal 2025 Acquisitions Stronger market position Revenue Expansion Drives Long-Term Margin Improvement Economies of scale Fixed cost absorption Completed December 2024 Deal Rationale & Key Updates • Fast tracked Organigram’s entry into the rapidly-growing cannabinoid beverages category and U.S. market.1 • Leverages the strength of the Collective Arts brand in the U.S. • Brick & mortar distribution in 11 states. • Launched DTC sales in 2025, increasing distribution to 20+ states; increased SKU count from two to nine. Completed March 2025 1 In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram’s U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.
Page 14
• Established the PDC with formation of a Center of Excellence at Moncton campus • Focused on developing the next generation of cannabis products, IP and technologies Over $345 Million Invested Strategic Investments from BAT: 2021 $221 Million • Creation of strategic investment pool named Jupiter, funded with $83.1 million • $41.5 million proceeds for general corporate purposes • Final $41.5 million tranche closed in February 2025 $125 Million 2024
Page 15
The $83.1 million Jupiter investment pool targets investments in emerging cannabis opportunities • All potential investments are made in alignment with Organigram’s strategic vision for the future, focusing on long-term sustainable growth and global cannabis leadership • Targeting investments that will enable Organigram to apply its industry-leading capabilities to new markets • Jupiter has deployed capital into two strategic investments:U.S.$2 million in OBX, and an approximate $21 million interest in Sanity Group • The Jupiter pool has $59 million remaining for deployment1 Priority Investment Pillars Sectors • U.S. regulated market and hemp-derived market Geographies • Germany, U.S. • Emerging global markets Categories & Tech • Non-combustible inhalation • Edibles • Beverages Value Chain Segments • Brands • Commercial Capabilities • Technology Investment Pool 1. The Jupiter pool has $59 million available for international strategic investments, of which $10 million is now temporarily u nrestricted to provide additional flexibility to the Company.
Page 16
• $21 million investment into German cannabis leader Sanity Group to establish foothold in rapidly growing German market and expand export volume to Europe. • Expansion of Organigram’s previously announced supply agreement with Sanity Group. • Opportunity to launch branded products in European market. GERMANY AND EUROPE Investments MANUFACTURING & FORMULATION • U.S.$2 million investment into U.S.-based OBX.1 • A hemp-derived cannabinoid producer. • Provides further footprint in the U.S. • Up to US$8 million investment (U.S$7 million invested to-date) into U.S.-based Phylos Bioscience to access flower-derived minor cannabinoids such as THCV and initiate the conversion of a portion of Organigram’s garden to more cost-effective seed- based production.1 • Moving toward catalogue of F1 stabilized seeds with consistent targeted traits. • 30% of flower harvest at Moncton facility was seed- based in Q1 Fiscal 2026. SEED-BASED TECHNOLOGY 1. In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram’s U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.
Page 17
Seeds: More Robust and Uniform Uniformity and Robustness of Seed Grow Clones Seeds
Page 18
1. Adjusted gross margin, adjusted gross margin %, and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to cautionary statement at the beginning of this document and the Company's Q1 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS. 2. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December 31, 2025 Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA1: $5.3 million (+273% year-over-year). Q1 FISCAL 2026 HIGHLIGHTS • Market Share in Canada: #1 in vapes, , #1 in milled flower, #1 in concentrates, #2 in pre-rolls #3 in edibles, #3 in dried flower2. • U.S. Expansion: Launched Collective Project & Fetch into Illinois and Wisconsin through new distribution partners, expanding US retail footprint to 11 states. • Powdery Mildew Resistance: Achieved proprietary genetic screening breakthrough that compresses powdery mildew resistance identification from months to days across a wide range of cultivars, enabling earlier selection and avoiding investment in non-resistant plants. Resistance is being bred into commercial cultivars to improve yield stability while reducing crop loss and production costs. • Yield Improvement: Kilograms harvested increased 43% to 28,645 compared to Q1 Fiscal 2025. The yield increases were achieved through nutrient and environmental enhancements, which contributed to lower per unit costs. Strong year-over-year growth supported by Canadian leadership and growing international sales, improving adjusted gross margin1.
Page 19
• Strong international sales trajectory • Continue to await EU-GMP certification, expected to increase sales and margins • Diversified customer base • Introduction of sales from entry into U.S. beverage market1 Increasing International Sales 1 In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram’s U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026. $2.2 $2.4 $4.1 $3.3 $6.1 $7.4 $9.6 $5.0 Q2 F24 Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 Q1 F26
Page 20
$37.6 $41.1 $44.7 $42.7 $65.6 $70.8 $80.1 $63.5 $57.4 $63.6 $69.9 $66.8 $102.8 $110.2 $123.3 97.3 $11.6 $14.6 $16.5 $14.3 $21.9 $24.2 $30.6 23.9 31% 36% 37% 33% 33% 34% 38% 38% Q2 F24 Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 Q1 F26 Net Revenue Gross Revenue Adj. Gross Margin Adj. Gross Margin % 1. Adjusted gross margin and adjusted gross margin %, are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to cautionary statement at the beginning of this document and the Company's Q1 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS. Revenue and Margins (millions) 1 1
Page 21
1. Adjusted EBITDA is a non-IFRS financial measures not defined by and does not have any standardized meanings under International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to cautionary statement at the beginning of this document and the Company's Q4 Fiscal 2025 MD&A for definitions and a reconciliation to IFRS. Adjusted EBITDA1 (millions) -$1.0 $3.5 $5.9 $1.4 $4.9 $5.7 $9.8 $5.3 Q2 F24 Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 Q1 F26
Page 22
Balance Sheet $63 million AS OF END OF Q1 Fiscal 2026: Total cash (including restricted cash & short-term investments) $7.6 million Unrestricted cash No material debt $59 million1 Jupiter Pool 1. The Jupiter pool has $59 million available for international strategic investments, of which $10 million is now temporarily u nrestricted to provide additional flexibility to the Company.
Page 23
Q1 FY26 Select Financial Metrics 1. Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to the cautionary statement at the beginning of this document and the Company’s Q1 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS. In 000’s unless otherwise indicated Select Key Financial Metrics (in $000s unless otherwise indicated) Q1-2026 Q1-2025 % Change Gross revenue 97,298 66,806 46% Excise taxes (33,760) (24,076) 40% Net revenue 63,538 42,730 49% Cost of sales 40,021 28,615 40% Gross margin before fair value changes to biological assets & inventories sold 23,517 14.115 67% Realized fair value on inventories sold and other inventory charges (16,911) (13,066) 29% Unrealized gain on changes in fair value of biological assets 16,709 12,765 31% Gross margin 23,315 13,814 69% Adjusted gross margin1 23,855 14,279 67% Adjusted gross margin %1 38% 33% 5% Selling (including marketing), general & administrative expenses 23,941 17,037 41% Net (loss) income 19,969 (22,957) nm Adjusted EBITDA1 5,265 1,410 273% Cash (used in) provided by operating activities before working capital changes 253 (6,288) nm Net cash provided by (used in) operating activities (16,013) (4,180) 283%
Page 24
Q1 FY26 Select Balance Sheet Metrics In 000’s unless otherwise indicated Select Balance Sheet Metrics (in $000s) December 31, 2025 September 30, 2025 % Change Cash & short-term investments (including restricted cash) 62,966 84,420 (25)% Biological assets & inventories 132,711 123,954 7% Other current assets 60,868 76,523 (20)% Accounts payable & accrued liabilities 71,079 89,247 (20)% Current portion of long-term debt 10 25 (60)% Working capital 162,494 158,738 2% Property, plant & equipment 123,482 122,977 nm Total assets 530,673 562,211 (6)% Total liabilities 161,217 213,081 (24)% Shareholders’ equity 369,456 349,130 6%
Page 25
Capital Structure 1. The preferred shares are eligible, under certain scenarios, to be converted into common shares equaling 14,198,539 consisting of the original preferred shares of 13,794,163 that convert into one common share and accretion amounts that accrue to the preferred shares at an annual rate of 7.5% per annum. Since the preferred shares were issued under the second and third tranches of the Jupiter private placement, they have collectively accrued 404,376 of additional common share conversion value. In 000’s unless otherwise indicated Capital Structure December 31, 2025 February 5, 2026 Common shares issued and outstanding 135,133 135,136 Preferred shares1 13,794 13,794 Options (Weighted Average Exercise Price: $10.17) 2,231 2,222 Warrants (Exercise Price: $3.65) 4,451 4,451 Top-up rights (Weighted Average Exercise Price: $1.90) 18,964 18,873 Restricted share units 3,486 3,403 Performance share units 2,193 2,034 Total fully diluted shares 180,252 179,912